GlassScriptPhysician profile
Raymond R Carrillo
NPI 1265511273
$599.91
in general payments reported to CMS, 2019-2025
14 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.71 · 2020: $20.62 · 2021: $17.27 · 2022: $69.32 · 2023: $53.04 · 2024: $260 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $150.36 | 2023-2025 | Tavneos, Aranesp, Parsabiv |
| Travere Therapeutics, INC. | $119.46 | 2024 | |
| Vifor Pharma, INC. | $113.15 | 2019-2022 | |
| Glaxosmithkline, LLC. | $24.21 | 2024 | Jesduvroq, Benlysta |
| Calliditas Therapeutics US INC. | $23.88 | 2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $22.97 | 2024 | Farxiga |
| Genzyme Corporation | $22.37 | 2023 | |
| Boston Scientific Corporation | $20.52 | 2024 | |
| Octapharma USA, INC. | $20.10 | 2024 | Octagam Immune Globulin (Human) |
| Fresenius USA Marketing, INC. | $19.06 | 2019 | |
| Baxter Healthcare | $17.46 | 2019 | |
| Lilly USA, LLC | $17.12 | 2023 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.10 | 2022 | |
| Daiichi Sankyo INC. | $13.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Carrillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.